FDA approves IND application for Ph 1 trial of KGX105 monotherapy in locally advanced or metastatic solid tumors
Dr. Weidong Jiang, Chief Executive Officer of KangaBio, commented: “The FDA’s clearance of KGX105, our second pipeline candidate, for clinical trials marks a pivotal moment in the company’s growth and reflects the increasing maturity of our prodrug platform technology. We look forward to thoroughly evaluating the safety and preliminary efficacy of KGX105 in this Phase 1 study, which will lay a solid foundation for its continued clinical development. The encouraging early clinical results from KGX101 have further validated our prodrug platform, offering valuable insights and confidence as we advance our pipeline. We extend our sincere gratitude to both existing and new investors for their continued trust and support. We are committed to accelerating the progress of our clinical programs and bringing new treatment hope to cancer patients around the world.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the